Mobile website
Archive > Volume 24 Issue 12 > 2017,24(12):1419-1423. DOI:10.3872/j.issn.1007-385X.2017.12.014 Prev Next
Clinical Research
Relation between nucleophosmin/B23 expression level in nasopharyngeal carcinoma tissues and therapeutic efficacy
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To investigate the relationship between nucleophosmin (NPM, B23, NO38 or NPM1) expression levels in tumor biopsy tissues as well as the proliferation index and the therapeutic efficacy in nasopharyngeal carcinoma (NPC) patients. Methods: One hundred and fifty- seven nasopharyngeal carcinoma patients, who were treated at Department of Pathology, Sun Yat-sen University cancer center during the period from January 1, 2001 till December 31, 2003 with preserved pre-treatment paraffin-embedded biopsy blocks, were randomly selected. The expressions of Ki-67 and NPM1 in the 157 sample tissues were determined by immunohistochemistry, respectively.The clinical data of patients were reviewed in detail, and the SPSS-16 soft ware was adopted for statistical analysis.Results: The levels of NPM1 were positively correlated with Ki-67 expression (r=0.445, P<0.01), but negatively correlated with regional lymph node status (N0, N1, N2, and N3; r=-0.235, P<0.01); however, it’s not correlated with primary tumor staging (T1, T2, T3 and T4; r=0.006, P>0.05) or clinical staging (r=-0.74, P>0.05). The expression of NPM1 was negatively correlated with the palpable rate of lymph node(s) (r=-0.196, P<0.05) in lymph node metastasis group, and negatively correlated with the primary lesion status after treatment (r=-0.349, P<0.05)in lymph node non-metastasis group. NPM1 expression was not significantly correlated with of the prognosis of patients. Conclusion: NPM1 expression in nasopharyngeal carcinoma tissues was positively correlated with Ki67 expression, proving NPM1 could promote the cell proliferation and might be used as an indicator for predicting the efficacy of individualized therapy for nasopharyngeal carcinoma patients.
Keywords:
Project Supported:
Clc Number:
